| Título : |
Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma |
| Tipo de documento : |
documento electrónico |
| Autores : |
Anders, Margarita, Autor ; Mattos, Angelo Z, Autor ; Debes, José D, Autor ; Beltrán, Oscar, Autor ; Coste, Pablo, Autor ; Juan Ignacio Marín Zuluaga, Autor ; Lopes Chagas, Aline, Autor ; Menéndez, Josemaría, Autor ; Carrera Estupiñán, Enrique, Autor ; Diaz Ferrer, Javier, Autor ; Mattos, Angelo Z, Autor ; Piñero, Federico, Autor |
| Fecha de publicación : |
2025 |
| Títulos uniformes : |
Annals of Hepatology
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Carcinoma; Drug therapy Adjuvant; Hepatocellular; Immunotherapy; Neoadjuvant therapy. |
| Resumen : |
Recent advances in the systemic treatment of advanced hepatocellular carcinoma (HCC) with immunotherapy have once again reignited discussion over the role of combined therapy in earlier stages. This year, different international meetings have presented recent results from clinical trials on adjuvant therapy alone (IMBrave-050) and combined with transarterial chemoembolization (EMERALD-1 and LEAP-12). Increased enthusiasm for the use of adjuvant and neoadjuvant therapy for liver transplantation, surgery, and local-regional treatment of HCC has been shown. However, the initial results from these trials should be interpreted cautiously as we wait for final analyses and effects on overall survival. In this position paper from the special interest group from the Latin American Association for the Study of Liver Diseases (ALEH), we underline the caveats of the applicability of these potential treatments in our region, explore points of agreement, and highlight areas of uncertainty. Moreover, we underscore the role of hepatologists in the clinical decision-making process and management of these patients. |
| Mención de responsabilidad : |
Marìa Margarita Anders, Angelo Z Mattos, José D Debes, Oscar Beltran, Pablo Coste, Juan Ignacio Marín, Aline Lopes Chagas, Josemaría Menéndez, Enrique Carrera Estupiñan, Javier Diaz Ferrer, Angelo A Mattos, Federico Piñero |
| Referencia : |
Anders MM, Mattos AZ, Debes JD, Beltran O, Coste P, Marín JI, Chagas AL, Menéndez J, Estupiñan EC, F |
| DOI (Digital Object Identifier) : |
10.1016/j.aohep.2025.101905 |
| PMID : |
40122521 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://pubmed.ncbi.nlm.nih.gov/40122521/ |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma [documento electrónico] / Anders, Margarita, Autor ; Mattos, Angelo Z, Autor ; Debes, José D, Autor ; Beltrán, Oscar, Autor ; Coste, Pablo, Autor ; Juan Ignacio Marín Zuluaga, Autor ; Lopes Chagas, Aline, Autor ; Menéndez, Josemaría, Autor ; Carrera Estupiñán, Enrique, Autor ; Diaz Ferrer, Javier, Autor ; Mattos, Angelo Z, Autor ; Piñero, Federico, Autor . - 2025. Obra : Annals of HepatologyIdioma : Inglés ( eng)
| Palabras clave : |
Carcinoma; Drug therapy Adjuvant; Hepatocellular; Immunotherapy; Neoadjuvant therapy. |
| Resumen : |
Recent advances in the systemic treatment of advanced hepatocellular carcinoma (HCC) with immunotherapy have once again reignited discussion over the role of combined therapy in earlier stages. This year, different international meetings have presented recent results from clinical trials on adjuvant therapy alone (IMBrave-050) and combined with transarterial chemoembolization (EMERALD-1 and LEAP-12). Increased enthusiasm for the use of adjuvant and neoadjuvant therapy for liver transplantation, surgery, and local-regional treatment of HCC has been shown. However, the initial results from these trials should be interpreted cautiously as we wait for final analyses and effects on overall survival. In this position paper from the special interest group from the Latin American Association for the Study of Liver Diseases (ALEH), we underline the caveats of the applicability of these potential treatments in our region, explore points of agreement, and highlight areas of uncertainty. Moreover, we underscore the role of hepatologists in the clinical decision-making process and management of these patients. |
| Mención de responsabilidad : |
Marìa Margarita Anders, Angelo Z Mattos, José D Debes, Oscar Beltran, Pablo Coste, Juan Ignacio Marín, Aline Lopes Chagas, Josemaría Menéndez, Enrique Carrera Estupiñan, Javier Diaz Ferrer, Angelo A Mattos, Federico Piñero |
| Referencia : |
Anders MM, Mattos AZ, Debes JD, Beltran O, Coste P, Marín JI, Chagas AL, Menéndez J, Estupiñan EC, F |
| DOI (Digital Object Identifier) : |
10.1016/j.aohep.2025.101905 |
| PMID : |
40122521 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://pubmed.ncbi.nlm.nih.gov/40122521/ |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaLatin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma / Anders, Margarita ; Mattos, Angelo Z ; Debes, José D ; Beltrán, Oscar ; Coste, Pablo ; Juan Ignacio Marín Zuluaga ; Lopes Chagas, Aline ; Menéndez, Josemaría ; Carrera Estupiñán, Enrique ; Diaz Ferrer, Javier ; Mattos, Angelo Z ; Piñero, Federico
